These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 32380758)

  • 1. Combination Drug Therapy for the Management of Alzheimer's Disease.
    Kabir MT; Uddin MS; Mamun AA; Jeandet P; Aleya L; Mansouri RA; Ashraf GM; Mathew B; Bin-Jumah MN; Abdel-Daim MM
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
    Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy for Alzheimer's disease.
    Patel L; Grossberg GT
    Drugs Aging; 2011 Jul; 28(7):539-46. PubMed ID: 21721598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy for the Treatment of Alzheimer's Disease: Recent Progress and Future Prospects.
    Shirbhate E; Patel VK; Tiwari P; Kore R; Veerasamy R; Mishra A; Rajak H
    Curr Top Med Chem; 2022; 22(22):1849-1867. PubMed ID: 36082857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies.
    Cummings JL
    Rev Neurol Dis; 2007; 4(2):57-62. PubMed ID: 17609636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of memantine for the treatment of dementia.
    Lo D; Grossberg GT
    Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
    Yamada M
    Brain Nerve; 2023 May; 75(5):464-469. PubMed ID: 37194514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease.
    Calhoun A; King C; Khoury R; Grossberg GT
    Expert Opin Pharmacother; 2018 Oct; 19(15):1711-1717. PubMed ID: 30244611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine.
    Zemek F; Drtinova L; Nepovimova E; Sepsova V; Korabecny J; Klimes J; Kuca K
    Expert Opin Drug Saf; 2014 Jun; 13(6):759-74. PubMed ID: 24845946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H; Grossberg GT
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
    Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
    Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Holmes C; Jones M; Jones R; Livingston G; McKeith I; Mittler P; Passmore P; Ritchie C; Robinson L; Sampson EL; Taylor JP; Thomas A; Burns A
    J Psychopharmacol; 2017 Feb; 31(2):147-168. PubMed ID: 28103749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease].
    Gallarda T; Lôo H
    Encephale; 2004; 30(1):69-79. PubMed ID: 15029079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine Derivatives as Multitarget Agents in Alzheimer's Disease.
    Marotta G; Basagni F; Rosini M; Minarini A
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32887400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease: early diagnosis and treatment.
    Chu LW
    Hong Kong Med J; 2012 Jun; 18(3):228-37. PubMed ID: 22665688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.